Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

House, Andrew A.; Wanner, Christoph; Sarnak, Mark J.; Piña, Ileana L.; McIntyre, Christopher W.; Komenda, Paul; Kasiske, Bertram L.; Deswal, Anita; deFilippi, Christopher R.; Cleland, John G.F.; Anker, Stefan D.; Herzog, Charles A.; Cheung, Michael; Wheeler, David C.; Winkelmayer, Wolfgang C.; McCullough, Peter A.; Abu‐Alfa, Ali K.; Amann, Kerstin; Aonuma, Kazutaka; Appel, Lawrence J.; Baigent, Colin; Bakris, George L.; Banerjee, Debasish; Boletis, John; Bozkurt, Biykem; Butler, Javed; Chan, Christopher T.; Costanzo, María Rosa; Dubin, Ruth F.; Filippatos, Gerasimos; Gikonyo, Betty M.; Gikonyo, Dan; Hajjar, Roger J.; Iseki, Kunitoshi; Ishii, Hideki; Knoll, Greg; Lenihan, Colin R.; Lentine, Krista L.; Lerma, Edgar V.; Macedo, Etienne; Mark, Patrick B.; Noiri, Eisei; Palazzuoli, Alberto; Pécoits-Filho, Roberto; Pitt, Bertram; Rigatto, Claudio; Rossignol, Patrick; Setoguchi, Soko; Sood, Manish M.; Störk, Stefan; Suri, Rita S.; Szummer, Karolina; Tang, Sydney C.W.; Tangri, Navdeep; Thompson, Aliza; Vijayaraghavan, Krishnaswami; Walsh, Michael D.; Wang, Angela Yee-Moon; Weir, Matthew R.

doi:10.1016/j.kint.2019.02.022

Cited by 297 publications

(264 citation statements)

References 132 publications

(117 reference statements)

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…In CKD patients and especially in ESRD patients requiring dialysis, the prevalence of coronary artery disease, sudden cardiac deaths, myocardial infarction, congestive heart failure, cerebrovascular disease, etc., is high [16,[101][102][103][104]. Mortality from cardiovascular causes rises with the deterioration of renal function [16].…”

Section: Cardiovascular Risk Related To Modifications Of Hdl Particlementioning

confidence: 99%

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease

Rysz

Gluba-Brzózka

Rysz-Górzyńska

et al. 2020

IJMS

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a worldwide health problem with steadily increasing occurrence. Significantly elevated cardiovascular morbidity and mortality have been observed in CKD. Cardiovascular diseases are the most important and frequent cause of death of CKD patients globally. The presence of CKD is related to disturbances in lipoprotein metabolism whose consequences are dyslipidemia and the accumulation of atherogenic particles. CKD not only fuels the reduction of high-density lipoprotein (HDL) cholesterol concentration, but also it modifies the composition of this lipoprotein. The key role of HDL is the participation in reverse cholesterol transport from peripheral tissues to the liver. Moreover, HDL prevents the oxidation of low-density lipoprotein (LDL) cholesterol by reactive oxygen species (ROS) and protects against the adverse effects of oxidized LDL (ox-LDL) on the endothelium. Numerous studies have demonstrated the ability of HDL to promote the production of nitric oxide (NO) by endothelial cells (ECs) and to exert antiapoptotic and anti-inflammatory effects. Increasing evidence suggests that in patients with chronic inflammatory disorders, HDLs may lose important antiatherosclerotic properties and become dysfunctional. So far, no therapeutic strategy to raise HDL, or alter the ratio of HDL subfractions, has been successful in slowing the progression of CKD or reducing cardiovascular disease in patients either with or without CKD.

show abstract

Section: Cardiovascular Risk Related To Modifications Of Hdl Particlementioning

confidence: 99%

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease

Rysz

Gluba-Brzózka

Rysz-Górzyńska

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Heart failure can be defined as myocardial inability to provide enough blood flow to other organs in the body including the brain, lungs and kidneys. Heart failure (HF) in chronic kidney disease (CKD) is increasing, and it is necessary to develop optimal strategies for its detection, prevention, diagnosis, and management [11]. Heart failure can be the result of acute or chronic conditions caused by structural or functional abnormalities or a sudden overload.…”

Section: Discussionmentioning

confidence: 99%

Prognosis of heart transplant patients in Mashhad University of Medical Sciences

Teshnisi

Vakilian

Zirak

et al. 2020

kitp

View full text Add to dashboard Cite

Introduction: Heart transplant is the ultimate treatment for patients with end-stage heart failure. Aim: To assess 50 heart transplant patients for underlying diseases, transplantation outcome and mortality rate during a 5-year follow-up program. Material and methods: Fifty heart transplant patients who underwent heart transplantation from 2012 to 2017 were assessed for underlying diseases, organ rejection, duration of hospitalization, extubation time, cardiac output and survival. Biopsy samples were obtained after surgery for evaluation of rejection. Results: Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) were the most common underlying diseases with prevalence of 56% and 12%, respectively. Significant improvement in ejection fraction was observed following heart transplant. Minimum and maximum extubation and hospitalization times were 3-408 hours and 1-51 days, respectively. Organ rejection evaluation 10 days after heart transplantation revealed that 50% of patients did not show any rejection while 10% had severe rejection. At 30 days post-operatively the number of patients with grade III rejection decreased to 2% while 56% of patients had no sign of rejection. The 5-year survival rate was 66% while infection and arrhythmia were the most common causes of death. Conclusions: DCM and ICM are considered the most prevalent underlying diseases in heart transplant candidates. Ejection fraction reached normal ranges following transplant, which provides good quality of life. Low incidence of severe acute rejection demonstrates the effectiveness of our immunosuppressive therapy. In the cases of increased rejection, the patient's immunosuppressive regimen was re-assessed accordingly.

show abstract

“…3.8 | Obesity increased hyper-filtration and kidney dysfunction in ALX −/− mice In the obesogenic setting, the heart and kidney coordinate the vicious cycle of pathophysiological stress and dysfunction of one feed-forward the maladaptive response to others. 37 Since ALX −/− mice displayed an age-related obesity phenotype with the signs of inflamed myocardium and defects in ECG, we determined whether obesity of ALX −/− mice impacts kidney function. Kidney functional data suggest higher glomerular filtration rate (GFR) (1.22-fold, P < .05) as a sign of hyperfiltration in the ALX −/− group compared with the WT group ( Figure 6A) with no change in t 1/2 ( Figure 6B).…”

Section: Alx Deficiency-induced Myocardium Endothelial Dysfunctionmentioning

confidence: 99%

Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity

et al. 2020

View full text Add to dashboard Cite

Abbreviations: ALX receptor, lipoxin receptor; Ca 2+ channel, calcium channel; CD31, cluster of differentiation 31; COX-2, cyclooxygenase-2; ECG, electrocardiogram; ECM, extracellular matrix; EDV, end-diastolic volume; ESV, end-systolic volume; eNOS, endothelial nitric oxide synthase; FPR2, formyl peptide receptor 2 (synonym as ALX); GFR, glomerular filtration rate; GLS, global longitudinal strain; HFpEF, heart failure with preserved ejection fraction; iNOS, inducible nitric oxide synthase; K + channel, potassium channel; Na 2+ channel, sodium channel; peNOS, phosphorylated eNOS; QMRI, quantitative magnetic resonance imaging; REE, resting energy expenditure; RCS, radial circumferential strain; TEE, total energy expenditure; VCO 2 , volume of CO 2 consumption; VO 2 , volume of O 2 consumption; WGA, wheat gram agglutinin.

show abstract

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Cited by 297 publications

References 132 publications

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease

The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease

Prognosis of heart transplant patients in Mashhad University of Medical Sciences

Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity

Contact Info

Product

Resources

About